Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Metastasis02:30

Metastasis

6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A regulatory circuitry driving a noradrenergic to mesenchymal transition highlights YAP/TAZ as critical players in neuroblastoma plasticity.

Cell reports·2026
Same author

Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction.

HemaSphere·2026
Same author

Menin inhibitors display differential <i>in vitro</i> sensitivity in <i>KMT2A</i>-rearranged infant acute lymphoblastic leukemia.

Leukemia & lymphoma·2026
Same author

Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia.

Cancer metastasis reviews·2025
Same author

Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia.

Nature reviews. Clinical oncology·2025
Same author

GATA 2 much: stemness and resistance in AML chemotherapy.

Blood·2025

Related Experiment Video

Updated: Feb 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

829

Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia.

Cécile Thirant1,2, Cécile Lopez1,2,3, Sébastien Malinge1,2,4

  • 1INSERM U1170, Villejuif, France.

Molecular & Cellular Oncology
|December 7, 2017
PubMed
Summary

The ETO2-GLIS2 fusion oncoprotein drives poor prognosis pediatric acute megakaryoblastic leukemia by controlling key genes. Targeting its complex stability offers a potential new therapeutic strategy for this aggressive cancer.

Keywords:
AMKLERGETO2GATAGLIS2NC128enhancerleukemiatranscription factor

More Related Videos

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Related Experiment Videos

Last Updated: Feb 17, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

829
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
10:33

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase

Published on: October 15, 2018

8.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • The ETO2-GLIS2 fusion oncoprotein is a key driver in pediatric acute megakaryoblastic leukemia (AMKL), a subtype associated with poor prognosis.
  • Understanding the molecular mechanisms by which ETO2-GLIS2 exerts its oncogenic effects is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of ETO2-GLIS2 in regulating gene expression through enhancer activity.
  • To explore the potential of targeting the ETO2-GLIS2 complex stability as a therapeutic strategy for AMKL.

Main Methods:

  • Analysis of enhancer activity in cells expressing ETO2-GLIS2.
  • Assessment of hematopoietic progenitor self-renewal and megakaryocytic differentiation.
  • Inhibition of ETO2-GLIS2 complex stability.

Main Results:

  • ETO2-GLIS2 was found to control enhancer activity at genes critical for hematopoietic progenitor self-renewal and megakaryocytic differentiation.
  • Inhibiting the stability of the ETO2-GLIS2 complex effectively suppressed these oncogenic properties.

Conclusions:

  • ETO2-GLIS2 plays a significant role in the pathogenesis of pediatric AMKL by modulating enhancer-driven gene expression.
  • Targeting ETO2-GLIS2 complex stability represents a promising novel therapeutic avenue for patients with this leukemia.